Investors

Investor Relations

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. 

NASDAQ: SCYX
$ 3.16 -0.12 (3.66%)
Day High: 3.28
Day Low:  3.08
Volume:    450,594
4:00 PM ET on
Jan 23, 2017

Delayed ~20 min., by eSignal.